• 1
    Filder IJ, Ellis LM. The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 1858.
  • 2
    Folgueras AR, Pendás AM, Sánchez LM et al. Matrix metalloproteinase in cancer: from new function to improved inhibition strategies. Int J Dev Biol 2004; 48: 41124.
  • 3
    Smalley W, Dubois RN. Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 120.
  • 4
    Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 333640.
  • 5
    Narayanan BA, Narayanan NK, Pittman B et al. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004; 10: 772737.
  • 6
    Herschman H. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 12540.
  • 7
    Sheng H, Shao MK, Washington MK et al. Prostaglandin E2 increases growth and mobility of colorectal carcinoma cells. J Biol Chem 2000; 276: 1807581.
  • 8
    Bunachanan FG, Wang F, Bargiacchi F, Dubois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 354517.
  • 9
    Pai R, Nakamura T, Moon S et al. Prostaglandins promote colon cancer cell invasion: signaling by cross-talk between distinct growth factor receptors. FASEB J 2003; 17: 16407.
  • 10
    Sugimoto Y, Narumiya S. Prostaglandin E receptor. J Biol Chem 2008; 282: 116137.
  • 11
    Amano H, Hayashi I, Endo H et al. Host prostaglandin E2–EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003; 197: 22132.
  • 12
    Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinoma. J Surg Oncol 2002; 80: 10510.
  • 13
    Yen J-H, Khayrullina T, Ganea D. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 2008; 111: 26070.
  • 14
    Mayoral R, Fernández-Martínez A, Boscá L et al. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 2005; 26: 75361.
  • 15
    Suzawa T, Miyaura C, Inada M et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for respective EPs. Endocrinology 2000; 141: 15549.
  • 16
    Fujita M, Hayashi I, Yamashina S et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005; 26: 2719.
  • 17
    Ikeda Y, Hayashi I, Kamoshita E et al. Host stromal bradikinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 2004; 64: 517885.
  • 18
    Kamoshita E, Ikeda Y, Fujita M et al. Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis. Am J Pathol 2006; 169: 145872.
  • 19
    Zuker S, Vacirca J. Role of metalloproteinase (MMPs) in colorectal cancer. Cancer Metastasis Review 2004; 23: 10117.
  • 20
    Pei D. Matrix metalloproteinase target protease-activated receptors on the tumor cell surface. Cancer Cell 2002; 7: 2078.
  • 21
    Van Kempen LCL, Coussens L. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002; 2: 2512.
  • 22
    Pan MR, Chuang LY, Hung WC. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in the lung cancer. FEBS Lett 2001; 508: 3658.
  • 23
    Reckamp KL, Gardner BK, Figlin RA et al. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 2008; 3: 11724.
  • 24
    Attiga FA, Fernandez PM, Weeraratna AT et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60: 462937.
  • 25
    Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 8207.
  • 26
    Ogawa F, Suzuki T, Oikawa A et al. Bone marrow-derived EP3-expression stromal cells enhance tumor-associated angiogenesis and tumor growth. Biochem Biophys Res Commun 2009; 382: 7205.
  • 27
    Amano H, Ando K, Minamida S et al. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol 2001; 87: 1818.
  • 28
    Hahm ER, Gho YS, Park S et al. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. BBRC 2004; 321: 33744.
  • 29
    Uzzo RG, Crispen PL, Golovine K et al. Diverse effects of zinc on NF-κB and AP-1 transcription factors: implication for prostate cancer progression. Carcinogenesis 2006; 27: 198090.
  • 30
    Callejas NA, Casado M, Díaz-Guerra MJM et al. Expression of cyclooxygenase-2 promotes the release of matrix metaloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 2001; 33: 8607.
  • 31
    Zhang Y, DeWitt DL, McNeely TB et al. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and metalloproteinase. J Clin Invest 1997; 99: 894900.
  • 32
    DiBattista JA, Martel-Pelletier J, Fujimoto N et al. Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts. Mediation by cyclic-AMP signalling pathway. Lab Invest 1994; 71: 2708.
  • 33
    Dormond O, Bezzi M, Mariotti A et al. Prostaglandin E2 promotes integrin αvβ3-dependent endothelial cell adhesion, Rac-activation and spreading through cAMP/PKA-dependent signaling. J Biol Chem 2002; 277: 4583846.